

Xuebing Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103350/publications.pdf>

Version: 2024-02-01

67
papers

3,378
citations

147566
31
h-index

149479
56
g-index

70
all docs

70
docs citations

70
times ranked

4393
citing authors

#	ARTICLE	IF	CITATIONS
1	Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 2467-2475.	6.7	408
2	Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2951-2962.	6.7	404
3	Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience. <i>Cell Transplantation</i> , 2013, 22, 2267-2277.	1.2	213
4	Transplantation of Human Bone Marrow Mesenchymal Stem Cell Ameliorates the Autoimmune Pathogenesis in MRL/lpr Mice. <i>Cellular and Molecular Immunology</i> , 2008, 5, 417-424.	4.8	173
5	The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. <i>Cellular and Molecular Immunology</i> , 2017, 14, 423-431.	4.8	167
6	Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. <i>Gut</i> , 2012, 61, 468-469.	6.1	113
7	Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. <i>Clinical Rheumatology</i> , 2012, 31, 157-161.	1.0	104
8	Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. <i>Clinical Rheumatology</i> , 2014, 33, 1611-1619.	1.0	91
9	Inhibition of Aberrant Circulating Tfh Cell Proportions by Corticosteroids in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2012, 7, e51982.	1.1	91
10	A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 2234-2245.	2.9	86
11	A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. <i>Stem Cell Reports</i> , 2018, 10, 933-941.	2.3	79
12	Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1285-1288.	0.5	68
13	Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. <i>Stem Cell Research and Therapy</i> , 2018, 9, 312.	2.4	66
14	Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis. <i>Scientific Reports</i> , 2015, 5, 12777.	1.6	65
15	ApoE ^{-/-} /Fas ^{-/-} C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. <i>Journal of Lipid Research</i> , 2007, 48, 794-805.	2.0	62
16	Hypoxia-inducible factor 1 in autoimmune diseases. <i>Cellular Immunology</i> , 2016, 303, 7-15.	1.4	58
17	Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015, 161, 209-216.	1.4	50
18	MicroRNA-663 induces immune dysregulation by inhibiting TGF- β 1 production in bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. <i>Cellular and Molecular Immunology</i> , 2019, 16, 260-274.	4.8	50

#	ARTICLE	IF	CITATIONS
19	Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. <i>Clinical and Experimental Medicine</i> , 2017, 17, 333-340.	1.9	49
20	Leptin and Neutrophil-Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2383-2393.	2.9	48
21	Mesenchymal Stem Cells from Patients with Rheumatoid Arthritis Display Impaired Function in Inhibiting Th17 Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	0.9	45
22	Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015, 34, 71-79.	1.0	43
23	Human Umbilical Cord Mesenchymal Stem Cells Inhibit T Follicular Helper Cell Expansion through the Activation of iNOS in Lupus-Prone B6.MRL- <i>Fas</i> ^{pr} Mice. <i>Cell Transplantation</i> , 2017, 26, 1031-1042.	1.2	43
24	Hypoxia Inducible Factor-1 Alpha Promotes Mesangial Cell Proliferation in Lupus Nephritis. <i>American Journal of Nephrology</i> , 2014, 40, 507-515.	1.4	42
25	Prognostic Indicators of Hospitalized Patients with Systemic Lupus Erythematosus: A Large Retrospective Multicenter Study in China. <i>Journal of Rheumatology</i> , 2011, 38, 1289-1295.	1.0	41
26	Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	40
27	Umbilical cord mesenchymal stem cells inhibit the differentiation of circulating T follicular helper cells in patients with primary Sjögren's syndrome through the secretion of indoleamine 2,3-dioxygenase. <i>Rheumatology</i> , 2015, 54, 332-342.	0.9	37
28	HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 1389-1393.	1.0	37
29	Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL- <i>Fas</i> ^{pr} mice via polarizing macrophage into an anti-inflammatory phenotype. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 597-605.	0.4	37
30	Umbilical Cord-Derived Mesenchymal Stem Cells Suppress Autophagy of T Cells in Patients with Systemic Lupus Erythematosus via Transfer of Mitochondria. <i>Stem Cells International</i> , 2016, 2016, 1-13.	1.2	36
31	Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis. <i>Clinical Rheumatology</i> , 2018, 37, 43-49.	1.0	36
32	Restored Immunosuppressive Effect of Mesenchymal Stem Cells on B Cells After Olfactory 1/Early B Cell Factor-Associated Zinc-Finger Protein Down-Regulation in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3413-3423.	2.9	35
33	Umbilical Cord-Derived Mesenchymal Stem Cells Inhibit Cadherin-11 Expression by Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	0.9	33
34	Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 165.	1.6	33
35	Mesenchymal Stem Cells Promote the Osteogenesis in Collagen-Induced Arthritic Mice through the Inhibition of TNF- α . <i>Stem Cells International</i> , 2018, 2018, 1-10.	1.2	31
36	Exacerbation of lupus nephritis by high sodium chloride related to activation of SGK1 pathway. <i>International Immunopharmacology</i> , 2015, 29, 568-573.	1.7	30

#	ARTICLE	IF	CITATIONS
37	Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. <i>Stem Cell Research and Therapy</i> , 2018, 9, 149.	2.4	30
38	Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 233.	2.2	30
39	Association of TNF- α with Impaired Migration Capacity of Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2014, 2014, 1-14.	0.9	28
40	Serum IFN- β Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1777-1785.	1.6	27
41	Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort. <i>PLoS ONE</i> , 2016, 11, e0168619.	1.1	22
42	Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 59-65.	1.6	19
43	Citrullinated fibrinogen impairs immunomodulatory function of bone marrow mesenchymal stem cells by triggering toll-like receptor. <i>Clinical Immunology</i> , 2018, 193, 38-45.	1.4	17
44	Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. <i>Clinical Rheumatology</i> , 2016, 35, 1521-1527.	1.0	14
45	Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases. <i>Clinical Rheumatology</i> , 2018, 37, 3337-3344.	1.0	14
46	Human SLE variant <i>NCF1</i> -R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 255-267.	0.5	14
47	Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1774-1783.	0.9	12
48	Discriminating infectious meningitis versus neuropsychiatric involvement in patients with systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2015, 34, 365-369.	1.0	10
49	Olf1/EBF associated zinc finger protein interfered with antinuclear antibody production in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R59.	1.6	8
50	Mesenchymal stem cells induced CD4+ T cell apoptosis in treatment of lupus mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 30-35.	1.0	8
51	Association between Type I interferon and depletion and dysfunction of endothelial progenitor cells in C57BL/6 mice deficient in both apolipoprotein E and Fas ligand. <i>Current Research in Translational Medicine</i> , 2018, 66, 71-82.	1.2	8
52	Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e80-e80.	0.5	8
53	Decreased serum ACE2 levels in patients with connective tissue diseases. <i>Rheumatology</i> , 2021, 60, 4401-4406.	0.9	8
54	CTLA-4 SNPs (CT60A/G, -1722T/C, -1661G/A, and -318C/T) and Systemic Lupus Erythematosus: A Meta-Analysis. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2014, 24, 89-100.	0.4	8

#	ARTICLE	IF	CITATIONS
55	Elevated Apoptosis and Impaired Proliferation Contribute to Downregulated Peripheral CD3 ⁺ CD4 ⁺ T Cells in Patients with Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	7
56	Association of anti-Ro52 autoantibodies with interstitial lung disease in connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216372.	0.5	7
57	Anti-Ro52 antibodies in clinical practice: A single-centre experience. <i>International Journal of Clinical Practice</i> , 2021, 75, e13679.	0.8	6
58	Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
59	Factors associated with event-free survival in Chinese patients with Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2021, 40, 1941-1948.	1.0	5
60	Creatinine clearance rate predicts prognosis of patients with systemic lupus erythematosus: a large retrospective cohort study. <i>Clinical Rheumatology</i> , 2021, 40, 2221-2231.	1.0	5
61	Prediction of diagnosis results of rheumatoid arthritis patients based on autoantibodies and cost-sensitive neural network. <i>Clinical Rheumatology</i> , 2022, 41, 2329-2339.	1.0	4
62	The relationship of polluted air and drinking water sources with the prevalence of systemic lupus erythematosus: a provincial population-based study. <i>Scientific Reports</i> , 2021, 11, 18591.	1.6	3
63	Association of Autoantibody Quantification With Systemic Lupus Erythematosus Disease Activity: Comment on the Article by Kim et al. <i>Arthritis and Rheumatology</i> , 2019, 71, 1588-1590.	2.9	1
64	MSCs relieve SLE by modulation of Th17 cells through MMPs-CCL2-CCR2-IL17 pathway. <i>Rheumatology & Autoimmunity</i> , 2021, 1, 30-39.	0.3	1
65	Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	1
66	Impaired olfactory neural circuit in patients with SLE at early stages. <i>Lupus</i> , 2021, 30, 1078-1085.	0.8	0
67	Predictors of improvement in disease activity in first hospitalized patients with systemic lupus erythematosus: a multicenter retrospective study of a Chinese cohort. <i>Clinical Rheumatology</i> , 0, , .	1.0	0